Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 2/2006

01-06-2006

Late-Onset Common Cancers in a Kindred with an Arg213Gln TP53 Germline Mutation

Authors: Mariëlle W. G. Ruijs, Senno Verhoef, Gea Wigbout, Roelof Pruntel, Arno N. Floore, Daphne de Jong, Laura J. van ′t Veer, Fred H. Menko

Published in: Familial Cancer | Issue 2/2006

Login to get access
Metadata
Title
Late-Onset Common Cancers in a Kindred with an Arg213Gln TP53 Germline Mutation
Authors
Mariëlle W. G. Ruijs
Senno Verhoef
Gea Wigbout
Roelof Pruntel
Arno N. Floore
Daphne de Jong
Laura J. van ′t Veer
Fred H. Menko
Publication date
01-06-2006
Publisher
Kluwer Academic Publishers
Published in
Familial Cancer / Issue 2/2006
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-005-4789-9

Other articles of this Issue 2/2006

Familial Cancer 2/2006 Go to the issue

OriginalPaper

Desmoid Tumors – a Characterization of Patients Seen at Mayo Clinic 1976–1999

OriginalPaper

A ‘Nonsense’ Mutation Leads to Aberrant Splicing of hMLH1 in a German Hereditary Non-polyposis Colorectal Cancer Family

Editorial

Familial Cancer (special issue) Breast Cancer Treatment and Genetics

OriginalPaper

Genotype Phenotype Correlation in Li-Fraumeni Syndrome Kindreds and its Implications for Management

OriginalPaper

BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis

OriginalPaper

The RET Mutation E768D Confers a Late-onset Familial Medullary Thyroid Carcinoma – Only Phenotype with Incomplete Penetrance: Implications for Screening and Management of Carrier Status
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits